ArticleNature methods2026
MassNet: billion-scale AI-ready mass spectral corpus empowering scalable deep learning in proteomics.
Article in Nature methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here we present MassNet, inspired by large-scale data corpora of text and images; MassNet is an artificial intelligence (AI)-ready data corpus for mass spectrometry (MS)-based proteomics. The corpus contains 1.5 billion tandem MS spectra from high-quality data-dependent acquisition (DDA) MS data across 35 species. Approximately 1.7 million peptide precursors are from human samples. We further present an AI-ready DDA data format called Mass Spectrometry DDA Tensor (MSDT) for compact and standardized storage, curation and reuse of data from multiple sources, which can be optionally converted to a Lightning Memory-Mapped Database for accelerated input/output in deep learning. On the basis of MassNet, we develop XuanjiNovo, a nonautoregressive transformer model that leverages a curriculum learning strategy for de novo peptide sequencing. XuanjiNovo achieves 38.35-143.57% improvement over state-of-the-art methods on human Astral data. MassNet also supports additional downstream tasks, including retention time prediction and PSM rescoring. MassNet represents a foundational MS-based proteomics data resource, marking a critical milestone for AI proteomics research.
Identifiers
42875595What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.